减轻全球酒精相关性肝病负担:行动蓝图
解决方案需多层面,聚焦人群和患者层面的干预,包括早期识别与干预、人群层面减少酒精消费(征税、减少可及性、限制促销)、针对当地社会经济现实的措施,以及新的医疗服务提供方式和平台,个体层面需整合医疗和AUD治疗。
要点
- 酒精相关性肝硬化和肝癌合计占全球所有死亡的1%,且负担预计增加。
核心结论
- 减少ALD相关发病和死亡需要多层面解决方案,聚焦早期识别和干预、人群层面减少酒精消费以及针对当地社会经济现实的措施。
研究设计与样本
- 原文未报告
主要发现
- 酒精相关性肝硬化和肝癌合计占全球所有死亡的1%,且该负担预计增加。
关键数值与推荐
- 简单筛查工具和算法可在人群层面用于识别酒精滥用,使用非侵入性血清和影像标志物诊断ALD,并对高风险ALD/AUD患者进行风险分层。
临床怎么用
- 原文未据此给出推荐
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alcohol-associated liver disease (ALD) is a major driver of global liver related morbidity and mortality. There are 2.4 billion drinkers (950 million heavy drinkers) and the lifetime prevalence of any alcohol use disorder (AUD) is 5.1%-8.6%. In 2017, global prevalence of alcohol-associated compensated and decompensated cirrhosis was 23.6 million and 2.5 million, respectively. Combined, alcohol-associated cirrhosis and liver cancer account for 1% of all deaths worldwide with this burden expected to increase. Solutions for this growing epidemic must be multi-faceted and focused on both population and patient-level interventions. Reductions in ALD-related morbidity and mortality require solutions that focus on early identification and intervention, reducing alcohol consumption at the population level (taxation, reduced availability and restricted promotion), and solutions tailored to local socioeconomic realities (unrecorded alcohol consumption, focused youth education). Simple screening tools and algorithms can be applied at the population level to identify alcohol misuse, diagnose ALD using non-invasive serum and imaging markers, and risk-stratify higher-risk ALD/AUD patients. Novel methods of healthcare delivery and platforms are needed (telehealth, outreach, use of non-healthcare providers, partnerships between primary and specialty care/tertiary hospitals) to proactively mitigate the global burden of ALD. An integrated approach that combines medical and AUD treatment is needed at the individual level to have the highest impact. Future needs include (1) improving quality of ALD data and standardizing care, (2) supporting innovative healthcare delivery platforms that can treat both ALD and AUD, (3) stronger and concerted advocacy by professional hepatology organizations, and (4) advancing implementation of digital interventions.
引用
- Asrani SK, Mellinger J, Arab JP, et al. Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action. Hepatology. 2021. PMID: 32986883. doi:10.1002/hep.31583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。